Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of CTP-543 (deuruxolitinib) in moderate to severe alopecia areata
2021-002365-18Phase 3Completed
- Sponsor
- Sun Pharmaceutical Industries, Inc.
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of deuruxolitinib in alopecia areata, sponsored by Sun Pharmaceutical Industries, Inc. Primary endpoint: Primary safety endpoint. Started Oct 2021; status: completed.
02
Drugs
deuruxolitinib
03
Conditions
alopecia areata
Beyond the preview
Go deeper on 2021-002365-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002365-18.